COMPOUNDING AND COMMERCIALIZATION
Leverage our manufacturing and logistics capabilities
ZERO Biotech's first subsidiary RIT Biotech, is operating a central radio-pharmacy production unit that serves all major hospitals in Hong Kong. The facility complies with local regulations under the international conditions, such as current Good Radio-pharmacy Practices (cGRPP), US Pharmacopeia (USP) 797 & International Atomic Energy Agency (IAEA) guidelines. RIT Biotech is the market leader, the daily production covers majority demand of the Hong Kong market. Our radiopharmaceuticals are used in diagnostic applications such as kidney, bone and cardiac imaging. RIT Biotech also produces and distributes therapeutic radiopharmaceuticals used in prostate cancer, neuroendocrine tumors, thyroid cancer and also with radio-medical devices treating liver cancer. RIT Biotech is the local expert on radiation related services and products. Please click the link below to learn more:
Since inception, ZERO Biotech Group has established itself as one of the leaders in Hong Kong’s nuclear medicine and made significant achievements. The subsidiary, RIT Biotech, obtained the first Hong Kong cGRPP licence for high standard radiopharmaceutical production and distribution. It also made significant breakthroughs and became the first company to distribute nuclear medicine cancer therapeutic drugs such as Lu-177, Ga-68, Tc-99m related products to all major hospitals of Hong Kong. ZERO Biotech Group is actively conducting clinical studies and trials in collaboration with Queen Mary Hospital and School of Medicine at the University of Hong Kong, sponsored by Li Ka Shing Foundation to the patients.
